Filing Details
- Accession Number:
- 0001610717-23-000260
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-09-06 20:03:48
- Reporting Period:
- 2023-09-01
- Accepted Time:
- 2023-09-06 20:03:48
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1628171 | Revolution Medicines Inc. | RVMD | Biological Products, (No Disgnostic Substances) (2836) | 472029180 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1800670 | Barbara Weber | C/O Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063 | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-09-01 | 3,854 | $1.12 | 19,679 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2023-09-01 | 11,146 | $4.73 | 30,825 | No | 4 | M | Direct | |
Common Stock | Disposition | 2023-09-01 | 15,000 | $35.07 | 15,825 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2023-09-01 | 3,854 | $0.00 | 3,854 | $1.12 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2023-09-01 | 11,146 | $0.00 | 11,146 | $4.73 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
9,635 | 2022-04-20 | 2028-04-19 | No | 4 | M | Direct |
1,851 | 2022-02-09 | 2029-08-08 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 14, 2022.
- Includes 5,200 restricted stock units.
- The transaction was executed in multiple trades in prices ranging from $35.00 to $35.24, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.